Jasper Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeetinder Singh Mahal
- Full Time Employees
- 64
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2200 Bridge Pkwy Redwood City CA United States of America 94065
- IPO Date
- Jan 10, 2020
- CIK
- 0001788028
- Website
- jaspertherapeutics.com
- Similar Companies
- Business
- Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cells and hematopoietic stem cells to treat chronic immunological, inflammatory, and mast cell-driven diseases. The company advances briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells; it is evaluating subcutaneous formulations of briquilimab in ongoing Phase 1b/2a trials including the BEACON study for chronic spontaneous urticaria (CSU) in patients refractory to antihistamines and omalizumab, the SPOTLIGHT study for chronic inducible urticaria (CIndU) such as cold urticaria and symptomatic dermographism, and the paused ETESIAN study for allergic asthma; prior evaluations of briquilimab also include its use as a conditioning agent in stem cell transplantation for hematologic malignancies, severe combined immunodeficiency, and sickle cell disease. Jasper Therapeutics operates in the biopharmaceutical sector, serving patients with mast cell-driven conditions like CSU, CIndU, and asthma, as well as those requiring stem cell therapies for blood disorders, with clinical trials conducted at sites in the US, EU, and Canada. Founded in 2018 and headquartered in Redwood City, California, the company maintains full worldwide rights to briquilimab across all indications and reports recent advancements such as continued patient enrollment in BEACON and SPOTLIGHT studies with additional data anticipated in early 2026 to support dose selection for a planned Phase 2b CSU trial mid-2026, a $45 million private placement in October 2024, and a $30 million public offering in October 2025.
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Here Are Monday’s Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell?
Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages
JSPR DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR
DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR